Previous 10 | Next 10 |
Gainers: MyMD Pharmaceuticals ( MYMD ) +23% . Clovis Oncology ( CLVS ) +22% . iRhythm Technologies ( IRTC ) +22% . Acer Therapeutics ( ACER ) +15% . Atreca ( BCEL ) +12% . Losers: RAPT Therapeutics ( RAPT ) -9% ...
On Thursday, Veru (NASDAQ: VERU) stock was getting a lot of love from analysts impressed by the latest news from the company. This translated to further gains for the share price, which saw a second consecutive healthy rise -- the stock closed more than 3% higher, outpacing the S&...
The oncology-focused biopharmaceutical company Veru ( NASDAQ: VERU ) has added ~11% in the pre-market Thursday after Jefferies argued that late-stage results for the company’s oral COVID therapy sabizabulin could warrant an emergency use nod from the FDA. Veru ( ...
Rivian Automotive ( NASDAQ: RIVN ) tops the list of big-name companies making notable moves in Wednesday's midday trading. Shares of the electric vehicle maker jumped following an update on its latest production and deliveries. Veru ( VERU ) rallied as well, thanks to the re...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Eos Energy Enterprises (NASDAQ: EOSE ) stock is soaring higher on Wednesday following an update from the energy storage systems company about new orders . According to Eos Energy, it has ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Sam Wordley / Shutterstock.com Veru (NASDAQ: VERU ) stock is on the move Wednesday after the oncology biopharmaceutical company published results from its Phase 3 clinical trial of sabizabulin . Sabiz...
Shares of Veru (NASDAQ: VERU) were up by more than 20.6% as of 10:06 a.m. ET Wednesday following the publication of overwhelmingly positive results from a phase 3 clinical trial of the biotech's drug candidate sabizabulin as a treatment for people hospitalized with severe cases of C...
Gainers: Inspira Technologies Oxy ( IINN ) +98% . Cano Health CANO +18% . Veru VERU +16% . Amylyx Pharmaceuticals ( AMLX ) +13% . Equillium ( EQ ) +12% . Losers: Applied Molecular Transport AMTI -26% . HTG Molecular D...
Phase 3 results of sabizabulin, Veru's ( NASDAQ: VERU ) anti-viral and anti-inflammatory oral drug candidate, have been published in the New England Journal of Medicine . Sabizabulin met its primary endpoint. The drug led to a 55.2% relative reduction in death...
- Phase 3 Clinical Study Met Primary and Key Secondary Endpoints - - Primary Endpoint: Sabizabulin Treatment Showed Statistically Significant and Clinically Meaningful 55.2% Reduction in Deaths Compared to Placebo in Moderate-Severe Hospitalized COVID-19 Patients - ...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...